Back to Search Start Over

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology

Authors :
Andrea Colliva
Lorena Zentilin
Hashim Ali
Luca Braga
Chiara Collesi
Serena Zacchigna
Furio Silvestri
Rossana Bussani
Edoardo Schneider
Fabrizio Zanconati
Giorgio Berlot
Maria Concetta Volpe
Mauro Giacca
Bussani, Rossana
Schneider, Edoardo
Zentilin, Lorena
Collesi, Chiara
Ali, Hashim
Braga, Luca
Volpe, Maria Concetta
Colliva, Andrea
Zanconati, Fabrizio
Berlot, Giorgio
Silvestri, Furio
Zacchigna, Serena
Giacca, Mauro
Source :
EBioMedicine
Publication Year :
2020

Abstract

Background COVID-19 is a deadly pulmonary disease with peculiar characteristics, which include variable clinical course and thrombophilia. A thorough understanding of the pathological correlates of the disease is still missing. Methods Here we report the systematic analysis of 41 consecutive post-mortem samples from individuals who died of COVID-19. Histological analysis is complemented by immunohistochemistry for cellular and viral antigens and the detection of viral genomes by in situ RNA hybridization. Findings COVID-19 is characterized by extensive alveolar damage (41/41 of patients) and thrombosis of the lung micro- and macro-vasculature (29/41, 71%). Thrombi were in different stages of organization, consistent with their local origin. Pneumocytes and endothelial cells contained viral RNA even at the later stages of the disease. An additional feature was the common presence of a large number of dysmorphic pneumocytes, often forming syncytial elements (36/41, 87%). Despite occasional detection of virus-positive cells, no overt signs of viral infection were detected in other organs, which showed non-specific alterations. Interpretation COVID-19 is a unique disease characterized by extensive lung thrombosis, long-term persistence of viral RNA in pneumocytes and endothelial cells, along with the presence of infected cell syncytia. Several of COVID-19 features might be consequent to the persistence of virus-infected cells for the duration of the disease. Funding This work was supported by a King's Together Rapid COVID-19 Call grant from King's College London. MG is supported by the European Research Council (ERC) Advanced Grant 787971 "CuRE" and by Programme Grant RG/19/11/34633 from the British Heart Foundation.

Details

Language :
English
Database :
OpenAIRE
Journal :
EBioMedicine
Accession number :
edsair.doi.dedup.....86cea2fe90eff81f42ba1d107393384e